Regulation of the Cdk inhibitor p27 and its deregulation in cancer
暂无分享,去创建一个
[1] K. Fujisawa,et al. Protein Kinase N (PKN) and PKN-Related Protein Rhophilin as Targets of Small GTPase Rho , 1996, Science.
[2] A. Zeleniuch‐Jacquotte,et al. Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. , 1999, The American journal of pathology.
[3] James M. Roberts,et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.
[4] James M. Roberts,et al. Cyclin E-CDK2 is a regulator of p27Kip1. , 1997, Genes & development.
[5] T. Hunter,et al. Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFβ-treated cells , 1996, Nature.
[6] M. Piris,et al. Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. , 1997, The American journal of pathology.
[7] G. Cooper,et al. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1 , 1997, Molecular and cellular biology.
[8] L. Hengst,et al. Translational Control of p27Kip1 Accumulation During the Cell Cycle , 1996, Science.
[9] G. Hannon,et al. p21-containing cyclin kinases exist in both active and inactive states. , 1994, Genes & development.
[10] G. Landberg,et al. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. , 1998, Blood.
[11] Stephen J. Elledge,et al. SKP1 Connects Cell Cycle Regulators to the Ubiquitin Proteolysis Machinery through a Novel Motif, the F-Box , 1996, Cell.
[12] James M. Roberts,et al. Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.
[13] J. Jones,et al. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. , 1996, Cancer research.
[14] James M. Roberts,et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. , 1995, Cancer research.
[15] L. Jin,et al. Aberrant p27kip1 expression in endocrine and other tumors. , 1997, The American journal of pathology.
[16] J. Massagué,et al. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. , 1995, Cancer research.
[17] Bruno Amati,et al. Phosphorylation‐dependent degradation of the cyclin‐dependent kinase inhibitor p27Kip1 , 1997, The EMBO journal.
[18] M. Loda,et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. , 1998, Cancer research.
[19] T. Hunter,et al. Dependence of Cyclin E-CDK2 Kinase Activity on Cell Anchorage , 1996, Science.
[20] G. Bradley,et al. Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. , 1998, The American journal of pathology.
[21] P. Yaswen,et al. Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells , 1997, Molecular and cellular biology.
[22] Andrea C. Carrano,et al. SKP 2 is required for ubiquitin-mediated degradation of the CDK inhibitor p 27 , 1999 .
[23] James M. Roberts,et al. The murine gene p27Kip1 is haplo-insufficient for tumour suppression , 1998, Nature.
[24] R. Kerbel,et al. TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1. , 1996, Oncogene.
[25] A. Murray,et al. Creative blocks: cell-cycle checkpoints and feedback controls , 1992, Nature.
[26] W. Krek,et al. p45 SKP2 promotes p27 Kip1 degradation , 1999 .
[27] C. Sherr. G1 phase progression: Cycling on cue , 1994, Cell.
[28] M Chilosi,et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. , 2000, Blood.
[29] S. Elledge,et al. A family of mammalian F-box proteins , 1999, Current Biology.
[30] D. Schiffer,et al. Proteasome-dependent degradation of p27/kip1 in gliomas. , 1999, Journal of neuropathology and experimental neurology.
[31] T. Hunt,et al. The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. , 1996, The EMBO journal.
[32] James M. Roberts,et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. , 1994, Genes & development.
[33] A. Kumar,et al. An additional role for the F-box motif: gene regulation within the Neurospora crassa sulfur control network. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[34] R. Kobayashi,et al. pl9 skp1 and p45 skp2 are essential elements of the cyclin A-CDK2 S phase kinase , 1995, Cell.
[35] W. Zwerschke,et al. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. , 1996, Oncogene.
[36] L. Hengst,et al. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells , 1994, Molecular and cellular biology.
[37] H. Sasano,et al. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[38] M. Pagano,et al. Enhanced Ribosomal Association of p27Kip1 mRNA Is a Mechanism Contributing to Accumulation during Growth Arrest* , 1997, The Journal of Biological Chemistry.
[39] N. Takuwa,et al. Ras activity late in G1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts , 1997, Molecular and cellular biology.
[40] J. LaBaer,et al. New functional activities for the p21 family of CDK inhibitors. , 1997, Genes & development.
[41] S. Shousha,et al. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[42] J. Slingerland,et al. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. , 1999, Annual review of medicine.
[43] A. Robles,et al. Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[44] K. Manova-Todorova,et al. Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1 , 1996, Cell.
[45] M. Monden,et al. Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence , 1999, Hepatology.
[46] W. Panje,et al. Prognostic Significance of p27 Expression in Carcinoma of the Oral Cavity and Oropharynx , 1999, The Laryngoscope.
[47] M. Raff,et al. Accumulation of the cyclin‐dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation , 1997, The EMBO journal.
[48] O. Hazeki,et al. Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. , 1995, Trends in biochemical sciences.
[49] M. Pagano,et al. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation , 1997, Leukemia.
[50] M. Kawada,et al. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway , 1997, Oncogene.
[51] Y. Yatabe,et al. p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. , 1998, Cancer research.
[52] S. Groshen,et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. , 1998, Journal of the National Cancer Institute.
[53] L. Hengst,et al. A cell cycle-regulated inhibitor of cyclin-dependent kinases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[54] G. Cattoretti,et al. Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. , 1998, Cancer research.
[55] Yanping,et al. Loss of the Cyclin-dependent Kinase Inhibitor 27Kq Protein in Human Prostate Cancer Correlates with Tumor Grade’ , 2005 .
[56] M. Kitagawa,et al. Down-regulation of p27 Kip1 by Two Mechanisms, Ubiquitin-mediated Degradation and Proteolytic Processing* , 1999, The Journal of Biological Chemistry.
[57] K Y Hui,et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.
[58] B. Amati,et al. Growth arrest by the cyclin‐dependent kinase inhibitor p27Kip1 is abrogated by c‐Myc. , 1996, The EMBO journal.
[59] G. Landberg,et al. Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation , 1999, Oncogene.
[60] F. Shepherd,et al. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. , 1999, Cancer research.
[61] J. Nesland,et al. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. , 1998, The American journal of pathology.
[62] W. Ansorge,et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27 , 1999, The EMBO journal.
[63] C. Bartram,et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. , 1995, Cancer research.
[64] S. Elledge,et al. How the Cyclin Became a Cyclin Regulated Proteolysis in the Cell Cycle , 1999, Cell.
[65] James M. Roberts,et al. The p21Cip1 and p27Kip1 CDK ‘inhibitors’ are essential activators of cyclin D‐dependent kinases in murine fibroblasts , 1999, The EMBO journal.
[66] G. Landberg,et al. Prognostic significance of p27Kip1 expression in colorectal cancer: a clinico‐pathological characterization , 1999, The Journal of pathology.
[67] J. Kato,et al. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1 , 1999, Nature.
[68] R. Assoian,et al. Anchorage-dependent Cell Cycle Progression , 1997, The Journal of cell biology.
[69] Juan F. García,et al. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. , 1999 .
[70] Ludger Hengst,et al. G1 control in mammalian cells , 1994, Journal of Cell Science.
[71] Esposito,et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. , 1997, Cancer research.
[72] M. Loda,et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.
[73] M. Pagano,et al. Cell cycle regulation by the ubiquitin pathway , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[74] W. Ansorge,et al. Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes , 1997, Oncogene.
[75] James M. Roberts,et al. CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.
[76] S. Semba,et al. Reduced Expression of Cyclin–dependent Kinase Inhibitor p27Kipl Is Associated with Advanced Stage and Invasiveness of Gastric Carcinomas , 1997, Japanese journal of cancer research : Gann.
[77] Nobuyuki Shishido,et al. Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.
[78] R. Kerbel,et al. Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents , 1996, Nature Medicine.
[79] A. Koff,et al. Cell-Free Degradation of p27kip1, a G1 Cyclin-Dependent Kinase Inhibitor, Is Dependent on CDK2 Activity and the Proteasome , 1999, Molecular and Cellular Biology.
[80] M. Roussel,et al. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[81] J. Palazzo,et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. , 1999, Cancer research.
[82] Leland Hartwell,et al. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells , 1992, Cell.
[83] Andrea C. Carrano,et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. , 1999, Genes & development.
[84] T. Tamiya,et al. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[85] Herman Yeger,et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.
[86] P. Beer-Romero,et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.
[87] A. Sewing,et al. Cyclins D1 and D2 mediate Myc‐induced proliferation via sequestration of p27Kip1 and p21Cip1 , 1999, The EMBO journal.
[88] Joseph R. Nevins,et al. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F , 1997, Nature.
[89] James M. Roberts,et al. A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.
[90] H. Saito,et al. Expression of protein p27 is associated with progression and prognosis in laryngeal cancer , 1999, The Laryngoscope.
[91] T. Visakorpi,et al. Androgen receptor gene and hormonal therapy failure of prostate cancer. , 1998, The American journal of pathology.
[92] M. Loda,et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. , 1997, Cancer research.
[93] J. Bartek,et al. Abrogation of p27Kip1 by cDNA Antisense Suppresses Quiescence (G0 State) in Fibroblasts* , 1996, The Journal of Biological Chemistry.
[94] L. Klotz,et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. , 1998, Cancer research.
[95] O. Cohen,et al. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[96] S. Dedhar,et al. Overexpression of the Integrin-linked Kinase Promotes Anchorage-independent Cell Cycle Progression* , 1997, The Journal of Biological Chemistry.
[97] James M. Roberts,et al. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein , 1996, The Journal of cell biology.
[98] David O. Morgan,et al. Principles of CDK regulation , 1995, Nature.
[99] T. Hunter,et al. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells , 1998, Oncogene.
[100] M. Tyers,et al. Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis. , 1998, Trends in genetics : TIG.
[101] Hong Sun,et al. p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27 , 1999, Current Biology.
[102] James M. Roberts,et al. Fibrillar Collagen Inhibits Arterial Smooth Muscle Proliferation through Regulation of Cdk2 Inhibitors , 1996, Cell.
[103] M. Dictor,et al. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. , 2000, Cancer.
[104] D. Schiffer,et al. p27/kip1 expression in human astrocytic gliomas , 1997, Neuroscience Letters.
[105] James M. Roberts,et al. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. , 1993, Science.
[106] M. Loda,et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. , 1998, The Journal of urology.
[107] K. Mimori,et al. p27 expression and gastric carcinoma , 1997, Nature Medicine.
[108] M. Vidal,et al. Identification of a family of human F-box proteins , 1999, Current Biology.